SEC61A1: A Protein with Potential as A Drug Target and Biomarker

Target Name: SEC61A1

NCBI ID: G29927

SEC61A1

SEC61A1: A Protein with Potential as A Drug Target and Biomarker

SEC61A1, also known as Sec61 alpha 1 subunit, is a protein that is expressed in various cell types throughout the body. It is a key component of the endoplasmic reticulum (ER), which is a system of organelles that retrieves and modifies proteins before they are transported to their final destinations.

One of the main functions of SEC61A1 is to transport proteins from the ER to the cytoplasm, where they can be involved in various cellular processes. It is also involved in the degradation of certain proteins that have become dysfunctional or have been expressed at higher levels than necessary.

SEC61A1 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

One of the reasons why SEC61A1 is of interest as a drug target is its involvement in the regulation of protein function. By targeting this protein and modifying its function, researchers may be able to develop new treatments for a variety of diseases.

Another potential use of SEC61A1 as a drug target is its role in the regulation of cellular processes that are often disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. By modulating the activity of SEC61A1, researchers may be able to develop new treatments for these conditions.

In addition to its potential as a drug target, SEC61A1 is also a potential biomarker for certain diseases. The levels of SEC61A1 have been shown to be elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By detecting the levels of SEC61A1 in body fluids or tissues, researchers may be able to develop new diagnostic tests for these conditions.

Overall, SEC61A1 is a protein that has important functions in various cellular processes throughout the body. Its potential as a drug target and biomarker make it an attractive target for researchers to explore for new treatments and diagnostic tools.

Protein Name: SEC61 Translocon Subunit Alpha 1

Functions: Component of SEC61 channel-forming translocon complex that mediates transport of signal peptide-containing precursor polypeptides across the endoplasmic reticulum (ER) (PubMed:12475939, PubMed:22375059, PubMed:28782633, PubMed:29719251, PubMed:32814900). Forms a ribosome receptor and a gated pore in the ER membrane, both functions required for cotranslational translocation of nascent polypeptides (PubMed:22375059, PubMed:28782633, PubMed:29719251). May cooperate with auxiliary protein SEC62, SEC63 and HSPA5/BiP to enable post-translational transport of small presecretory proteins (PubMed:22375059, PubMed:29719251). The SEC61 channel is also involved in ER membrane insertion of transmembrane proteins: it mediates membrane insertion of the first few transmembrane segments of proteins, while insertion of subsequent transmembrane regions of multi-pass membrane proteins is mediated by the multi-pass translocon (MPT) complex (PubMed:32820719, PubMed:36261522). The SEC61 channel cooperates with the translocating protein TRAM1 to import nascent proteins into the ER (PubMed:8616892). Controls the passive efflux of calcium ions from the ER lumen to the cytosol through SEC61 channel, contributing to the maintenance of cellular calcium homeostasis (PubMed:28782633). Plays a critical role in nephrogenesis, specifically at pronephros stage (By similarity)

The "SEC61A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC61A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets